Business Wire

GI-TONE-NUMATA

17.1.2022 09:02:13 CET | Business Wire | Press release

Share
Gunma Prefecture's Geographical Indication “GI Tone-Numata” Sake Kicks Off Its Overseas Sales on January 17!

Sake’s geographical indication, “GI Tone-Numata,” which consists of four sake breweries in the Tone-Numata area of Gunma Prefecture in Japan, requires that the breweries make the most of the local water and climate, and that the type of rice used as the raw material be one of the following: Yukihotaka, Gohyakumangoku, or Koshihikari. In addition, only yeast from the local area (Gunma KAZE yeast, Gunma G2 yeast, and brewer's house yeast) can be used, and vintage can be indicated under certain conditions, so only those that meet the extremely strict criteria are certified.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006144/en/

According to Mr. Shinya Tasaki, Chairman of the Japan Sommelier Association, "GI Tone-Numata is equivalent to PDO in Europe or AOC in French wine and is expected to attract worldwide attention in the future." On January 17, "GI Tone-Numata" sake as a set of 7 bottles will be released for sale in overseas markets.

The seven kinds of “GI Tone-Numata” sake commonly have a transparent, pale gold color, and an aroma that contains the note of freshly made rice cakes, fruit, almond jelly, green grass, and fresh greenery. The flavors are characterized by a refreshing acidity, a bitterness that brings richness, a mellow umami and sweetness derived from rice, and a clear impression.

These seven types of certified sake, from sparkling sake for the “kanpai,” to full-flavored sake for the main course, then sweet dessert sake at the end of the meal, can be paired with French cuisine course meals. They go well with ingredients that are difficult to pair with wine, such as fresh tomatoes and eggs.

  • The lineup of GI Tone-Numata certified sake and (the examples of) recommended food parings
  1. MIZUBASHO Yukihotaka AWA SAKE (NAGAI SAKE INC.) and Caprese Salad and Fruit Tomatoes
  2. Shin Tsuchida GI Tone-Numata Koshihikari (Tsuchida Sake Brewery Co., Ltd.) and Cold Roasted Duck with orange sauce
  3. Sadaijin Koshihikari (Otone Sake Brewery) and Penne carbonara
  4. Shin Tsuchida GI Tone-Numata Yukihotaka (Tsuchida Sake Brewery Co., Ltd.) and Scallop Meuniere, Provencal
  5. MIZUBASHO Yukihotaka Junmai Daiginjo (NAGAI SAKE INC.) and Vichyssoise
  6. TONENISHIKI JUNMAI KOSHIHIKARI 90 (Nagai-honke Inc.) and Akagi Chicken Fricassee with steamed vegetables
  7. MIZUBASHO Yukihotaka Dessert Sake (NAGAI SAKE INC.) and Strawberry Shortcake

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye